Comparing 3 Schedules of Alimta Plus Gemzar

Lilly

Status and phase: Completed; Phase 2

Conditions: Lung Neoplasms; Neoplasms; Carcinoma, Non-Small-Cell Lung

Treatments: Drug: Pemetrexed (Alimta) in combination with gemcitabine (Gemzar)

Study type: Interventional

Funder types: Industry

Identifiers

NCT00034606

H3E-MC-JMEL

5115

Details and patient eligibility

About

The purpose of the study is to measure tumor response rates for three schedules of Alimta(LY231514) in combination with gemcitabine in patients with locally advanced or metastatic non small cell lung cancer who have received no prior chemotherapy regimen.

Sex: All

Ages: 18+ years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• Diagnosis of non-small lung cancer
• No prior chemotherapy
• Able to care for self

Exclusion criteria

• An ongoing infection
• Pregnancy or breast feeding
• Other serious medical condition
• Cancer that has spread to the brain
• Inability to take folic acid

Trial design

Primary purpose: Treatment

Allocation: Randomized

Interventional model: Parallel Assignment

Masking: None (Open label)